Frauke Schimmöller

2.7k total citations
35 papers, 1.9k citations indexed

About

Frauke Schimmöller is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Frauke Schimmöller has authored 35 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 17 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Frauke Schimmöller's work include PI3K/AKT/mTOR signaling in cancer (10 papers), Advanced Breast Cancer Therapies (9 papers) and Cellular transport and secretion (9 papers). Frauke Schimmöller is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (10 papers), Advanced Breast Cancer Therapies (9 papers) and Cellular transport and secretion (9 papers). Frauke Schimmöller collaborates with scholars based in United States, Spain and France. Frauke Schimmöller's co-authors include Howard Riezman, Suzanne R. Pfeffer, Stephan Schröder, Iris Simón, Birgit Singer‐Krüger, Elva Dı́az, Charles Barlowe, Ute Krüger, Tamara L. Doering and Christine Sütterlin and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Frauke Schimmöller

35 papers receiving 1.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Frauke Schimmöller	1.2k	980	386	336	200	35	1.9k
Agnes Ang	763 0.6×	638 0.7×	144 0.4×	339 1.0×	198 1.0×	32	1.4k
Gustavo Pacheco–Rodriguez	895 0.8×	546 0.6×	312 0.8×	446 1.3×	711 3.6×	64	2.0k
Sudharshan Eathiraj	893 0.8×	597 0.6×	119 0.3×	179 0.5×	144 0.7×	38	1.5k
Narendra Thapa	1.1k 0.9×	603 0.6×	94 0.2×	226 0.7×	150 0.8×	32	1.7k
Robert McEwen	1.1k 1.0×	566 0.6×	495 1.3×	613 1.8×	105 0.5×	37	2.2k
Ari Hashimoto	1.4k 1.1×	643 0.7×	126 0.3×	588 1.8×	100 0.5×	47	2.3k
Roser Pinyol	972 0.8×	550 0.6×	257 0.7×	274 0.8×	60 0.3×	24	1.8k
Chitose Oneyama	1.6k 1.3×	378 0.4×	110 0.3×	327 1.0×	82 0.4×	61	2.1k
Yaara Zwang	1.5k 1.3×	709 0.7×	158 0.4×	645 1.9×	44 0.2×	19	2.1k
I. Hiles	2.1k 1.8×	585 0.6×	65 0.2×	482 1.4×	143 0.7×	12	2.6k

Countries citing papers authored by Frauke Schimmöller

Since Specialization

Citations

This map shows the geographic impact of Frauke Schimmöller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frauke Schimmöller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frauke Schimmöller more than expected).

Fields of papers citing papers by Frauke Schimmöller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frauke Schimmöller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frauke Schimmöller. The network helps show where Frauke Schimmöller may publish in the future.

Co-authorship network of co-authors of Frauke Schimmöller

This figure shows the co-authorship network connecting the top 25 collaborators of Frauke Schimmöller. A scholar is included among the top collaborators of Frauke Schimmöller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frauke Schimmöller. Frauke Schimmöller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Llombart‐Cussac, Antonio, José Manuel Pérez-García, María Gión, et al.. (2024). Abstract PO1-20-02: MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC). Cancer Research. 84(9_Supplement). PO1–20. 1 indexed citations

Chen, Jessica W., William Jacot, Javier Cortés, et al.. (2023). ER +, HER2 − advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Molecular Oncology. 17(10). 2000–2016. 1 indexed citations

Hutchinson, Katherine E., Jessica W. Chen, Heidi Savage, et al.. (2023). Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers. Genome Medicine. 15(1). 28–28. 14 indexed citations

Dent, Susan, Javier Cortés, Young‐Hyuck Im, et al.. (2020). Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. Annals of Oncology. 32(2). 197–207. 116 indexed citations

Jacot, William, Susan Dent, Javier Cortés, et al.. (2020). 3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer. Annals of Oncology. 31. S16–S16. 1 indexed citations

Baselga, José, Susan Dent, Javier Cortés, et al.. (2018). Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology. 36(18_suppl). LBA1006–LBA1006. 105 indexed citations

Daud, Adil, Harriet M. Kluger, Razelle Kurzrock, et al.. (2017). Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. British Journal of Cancer. 116(4). 432–440. 52 indexed citations

Baselga, José, Michelino De Laurentiis, Véronique Dièras, et al.. (2016). SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours. Annals of Oncology. 27. vi99–vi99. 7 indexed citations

Baselga, José, Javier Cortés, Michelino De Laurentiis, et al.. (2016). Abstract OT1-03-14: SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors. Cancer Research. 76(4_Supplement). OT1–3. 2 indexed citations

10.

Basch, Ethan, Karen A. Autio, Matthew R. Smith, et al.. (2014). Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. European Urology. 67(2). 310–318. 31 indexed citations

11.

Dai, Jinlu, Honglai Zhang, Jill M. Keller, et al.. (2013). Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions. Clinical Cancer Research. 20(3). 617–630. 79 indexed citations

12.

Bennett, Antonia V., Sonya Eremenco, Christian Scheffold, et al.. (2013). Mode Equivalence of Interactive Voice Response (IVR) and Paper Versions of the Brief Pain Inventory (BPI) “Worst Pain” Item in Metastatic Castrate Resistant Prostate Cancer (mCRPC) Evaluated Conceptually Using Qualitative Methods. Value in Health. 16(7). A601–A601. 1 indexed citations

13.

Daud, Adil, Harriet M. Kluger, Gerald M. Edelman, et al.. (2013). Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 31(15_suppl). 9094–9094. 12 indexed citations

14.

Dai, Jinlu, et al.. (2012). Abstract 2851: Cabozantinib (XL184) inhibits prostate tumor growth and bone lesion development. Cancer Research. 72(8_Supplement). 2851–2851. 1 indexed citations

15.

Gordon, Michael S., Harriet M. Kluger, Geoffrey I. Shapiro, et al.. (2012). Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT).. Journal of Clinical Oncology. 30(15_suppl). 8531–8531. 17 indexed citations

16.

Schimmöller, Frauke, et al.. (2011). Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone.. Molecular Cancer Therapeutics. 10(11_Supplement). A233–A233. 12 indexed citations

17.

Gordon, Michael, Gerald M. Edelman, Matt D. Galsky, et al.. (2010). An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). TPS188–TPS188. 4 indexed citations

18.

Schimmöller, Frauke, et al.. (1998). Characterization of a 76 kDa endosomal, multispanning membrane protein that is highly conserved throughout evolution. Gene. 216(2). 311–318. 45 indexed citations

19.

Schimmöller, Frauke, Iris Simón, & Suzanne R. Pfeffer. (1998). Rab GTPases, Directors of Vesicle Docking. Journal of Biological Chemistry. 273(35). 22161–22164. 268 indexed citations

20.

Schimmöller, Frauke, Christian Itin, & Suzanne R. Pfeffer. (1997). Vesicle traffic: Get your coat!. Current Biology. 7(4). R235–R237. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact